WEKO3
-
RootNode
アイテム
Improvement of intratumor microdistribution of PEGylated liposome via tumor priming by metronomic S-1 dosing
https://tokushima-u.repo.nii.ac.jp/records/2008094
https://tokushima-u.repo.nii.ac.jp/records/20080947daac49b-2557-4660-a382-af887bb372af
| 名前 / ファイル | ライセンス | アクション |
|---|---|---|
ijn_11_5573.pdf (1.48 MB)
|
.png)
|
| Item type | 文献 / Documents(1) | |||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 公開日 | 2021-02-10 | |||||||||||||||||||||||||||||||
| アクセス権 | ||||||||||||||||||||||||||||||||
| アクセス権 | open access | |||||||||||||||||||||||||||||||
| 資源タイプ | ||||||||||||||||||||||||||||||||
| 資源タイプ識別子 | http://purl.org/coar/resource_type/c_6501 | |||||||||||||||||||||||||||||||
| 資源タイプ | journal article | |||||||||||||||||||||||||||||||
| 出版社版DOI | ||||||||||||||||||||||||||||||||
| 関連識別子 | https://doi.org/10.2147/IJN.S119069 | |||||||||||||||||||||||||||||||
| 関連名称 | 10.2147/IJN.S119069 | |||||||||||||||||||||||||||||||
| 出版タイプ | ||||||||||||||||||||||||||||||||
| 出版タイプ | VoR | |||||||||||||||||||||||||||||||
| 出版タイプResource | http://purl.org/coar/version/c_970fb48d4fbd8a85 | |||||||||||||||||||||||||||||||
| タイトル | ||||||||||||||||||||||||||||||||
| タイトル | Improvement of intratumor microdistribution of PEGylated liposome via tumor priming by metronomic S-1 dosing | |||||||||||||||||||||||||||||||
| タイトル別表記 | ||||||||||||||||||||||||||||||||
| その他のタイトル | S-1 mediated tumor priming enhances intratumor liposomal fate | |||||||||||||||||||||||||||||||
| 著者 |
ドイ, ユウスケ
× ドイ, ユウスケ
× Lila, Amr S Abu
× マツモト, ハルナ
× オカダ, トモコ
× 清水, 太郎× 石田, 竜弘
WEKO
1145
|
|||||||||||||||||||||||||||||||
| 抄録 | ||||||||||||||||||||||||||||||||
| 内容記述 | The efficient delivery of nanocarrier-based cancer therapeutics into tumor tissue is problematic. Structural abnormalities, tumor vasculature heterogeneity, and elevated intratumor pressure impose barriers against the preferential accumulation of nanocarrier-based cancer therapeutics within tumor tissues and, consequently, compromise their therapeutic efficacy. Recently, we have reported that metronomic S-1, orally available tegafur formulation, dosing synergistically augmented the therapeutic efficacy of oxaliplatin (l-OHP)-containing PEGylated liposome without increasing the toxicity in animal model. However, the exact mechanism behind such synergistic effect was not fully elucidated. In this study, therefore, we tried to shed the light on the contributions of metronomic S-1 dosing to the enhanced accumulation and/or spatial distribution of PEGylated liposome within tumor tissue. Tumor priming with metronomic S-1 treatment induced a potent apoptotic response against both angiogenic endothelial cells and tumor cells adjacent to tumor blood vessels, resulting in enhanced tumor blood flow via transient normalization of tumor vasculature, along with alleviation of intratumor pressure. Such a change in the tumor microenvironment imparted by S-1 treatment allows efficient delivery of PEGylated liposome to tumor tissue and permits their deep penetration/distribution into the tumor mass. Such a priming effect of S-1 dosing can be exploited as a promising strategy to enhance the therapeutic efficacy of nanocarrier-based cancer therapeutics suffering from inadequate/heterogeneous delivery to tumor tissues. | |||||||||||||||||||||||||||||||
| キーワード | ||||||||||||||||||||||||||||||||
| 主題 | tumor microenvironment | |||||||||||||||||||||||||||||||
| キーワード | ||||||||||||||||||||||||||||||||
| 主題 | metronomic chemotherapy | |||||||||||||||||||||||||||||||
| キーワード | ||||||||||||||||||||||||||||||||
| 主題 | S-1 | |||||||||||||||||||||||||||||||
| キーワード | ||||||||||||||||||||||||||||||||
| 主題 | liposome | |||||||||||||||||||||||||||||||
| キーワード | ||||||||||||||||||||||||||||||||
| 主題 | nanocarrier | |||||||||||||||||||||||||||||||
| キーワード | ||||||||||||||||||||||||||||||||
| 主題 | EPR effect | |||||||||||||||||||||||||||||||
| 書誌情報 |
en : International Journal of Nanomedicine 巻 11, p. 5573-5582, 発行日 2016-10-25 |
|||||||||||||||||||||||||||||||
| 収録物ID | ||||||||||||||||||||||||||||||||
| 収録物識別子タイプ | ISSN | |||||||||||||||||||||||||||||||
| 収録物識別子 | 11782013 | |||||||||||||||||||||||||||||||
| 収録物ID | ||||||||||||||||||||||||||||||||
| 収録物識別子タイプ | NCID | |||||||||||||||||||||||||||||||
| 収録物識別子 | AA1215861X | |||||||||||||||||||||||||||||||
| 出版者 | ||||||||||||||||||||||||||||||||
| 出版者 | Dove Medical Press | |||||||||||||||||||||||||||||||
| 権利情報 | ||||||||||||||||||||||||||||||||
| 権利情報 | © 2016 Doi et al. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). | |||||||||||||||||||||||||||||||
| EID | ||||||||||||||||||||||||||||||||
| 識別子 | 320421 | |||||||||||||||||||||||||||||||
| 言語 | ||||||||||||||||||||||||||||||||
| 言語 | eng | |||||||||||||||||||||||||||||||
